Linked Life Data

17647197

Source:http://linkedlifedata.com/resource/pubmed/id/17647197

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2007-7-24
pubmed:abstractText
Survivin is a recently described inhibitor of apoptosis and mitotic regulator which is selectively over-expressed in human tumors. Its expression rate is predictive of disease progression, early recurrences and resistance to therapy. Up-regulation of survivin in oral pre-malignant lesions (OPL) and in oral squamous cell carcinoma (OSCC) has already been demonstrated in previous studies. A critical step for activation of survivin has been identified in the phosphorylation on Thr34 by the main mitotic kinase p34cdc2-cyclin B1. The aim of this work was to investigate the relationship between survivin, its phosphorylated active form (p-survivin) and M-phase promoting factor (MPF), p34cdc2-cyclin B1 in oral carcinogenesis. 32 OSCCs and 17 OPLs from surgical specimens were studied for cyclin B1, p-survivin, survivin, and p34cdc2 expression by immunohistochemistry. All cases of OSCC expressed survivin and its expression rate was correlated to p-survivin levels (P<0.05). Cyclin B1 was positive in 80% of cases, while p-34cdc2 was over-expressed in all OSCCs. All OPLs associated with OSCC expressed survivin and its levels were correlated to p-survivin levels (P<0.05). Cyclin B1 was positive in 70% of cases, while p-34cdc2 was positive in all OPLs. In conclusion, this study demonstrated that MPF, survivin and p-survivin are expressed during early and late phase of oral carcinogenesis. MPF proteins, which are co-expressed on mitotic apparatus, could represent a potential target for therapies based on manipulation of survivin phosphorylation, which would induce apoptosis in cancer cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1699-5848
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1241-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:17647197-CDC2 Protein Kinase, pubmed-meshheading:17647197-Carcinoma, Squamous Cell, pubmed-meshheading:17647197-Cyclin B, pubmed-meshheading:17647197-Cyclin B1, pubmed-meshheading:17647197-Female, pubmed-meshheading:17647197-Humans, pubmed-meshheading:17647197-Immunoenzyme Techniques, pubmed-meshheading:17647197-Inhibitor of Apoptosis Proteins, pubmed-meshheading:17647197-Male, pubmed-meshheading:17647197-Maturation-Promoting Factor, pubmed-meshheading:17647197-Microtubule-Associated Proteins, pubmed-meshheading:17647197-Middle Aged, pubmed-meshheading:17647197-Mouth Neoplasms, pubmed-meshheading:17647197-Neoplasm Proteins, pubmed-meshheading:17647197-Phosphorylation, pubmed-meshheading:17647197-Precancerous Conditions, pubmed-meshheading:17647197-Tumor Markers, Biological
pubmed:year
2007
pubmed:articleTitle
Survivin phosphorylation and M-phase promoting factor in oral carcinogenesis.
pubmed:affiliation
Department of Surgical Science, Section of Pathology, University of Foggia, Foggia, Italy.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't